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in regulating signaling downstream of the receptor as well 
as controlling receptor stability. We found that mutation 
of Y842 in the FLT3-ITD oncogenic mutant background 
reduced cell viability and increased apoptosis. Further-
more, the introduction of the Y842 mutation in the FLT3-
ITD background led to a dramatic reduction in in  vitro 
colony forming capacity. Additionally, mice injected with 
cells expressing FLT3-ITD/Y842F displayed a significant 
delay in tumor formation, compared to FLT3-ITD express-
ing cells. Microarray analysis comparing gene expression 
regulated by FLT3-ITD versus FLT3-ITD/Y842F dem-
onstrated that mutation of Y842 causes suppression of 
anti-apoptotic genes. Furthermore, we showed that cells 
expressing FLT3-ITD/Y842F display impaired activity of 
the RAS/ERK pathway due to reduced interaction between 
FLT3 and SHP2 leading to reduced SHP2 activation. Thus, 
we suggest that Y842 is critical for FLT3-mediated RAS/
ERK signaling and cellular transformation.
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FLT3  Fms-like tyrosine kinase
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MET  Hepatocyte growth factor receptor
RTK  Receptor tyrosine kinase
SH2  Src homology 2
Abstract The type III receptor tyrosine kinase FLT3 is 
frequently mutated in acute myeloid leukemia. Oncogenic 
FLT3 mutants display constitutive activity leading to aber-
rant cell proliferation and survival. Phosphorylation on 
several critical tyrosine residues is known to be essential 
for FLT3 signaling. Among these tyrosine residues, Y842 
is located in the so-called activation loop. The position of 
this tyrosine residue is well conserved in all receptor tyros-
ine kinases. It has been reported that phosphorylation of 
the activation loop tyrosine is critical for catalytic activ-
ity for some but not all receptor tyrosine kinases. The role 
of Y842 residue in FLT3 signaling has not yet been stud-
ied. In this report, we show that Y842 is not important for 
FLT3 activation or ubiquitination but plays a critical role 
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous hemat-
opoietic disorder. The molecular genetics of AML has been 
thoroughly investigated identifying loss-of-function muta-
tions in transcription factors and gain-of-function mutations 
in receptor tyrosine kinases. The most commonly mutated 
genes include NPM1, CEBPA, TET2, IDH, DNMT3A and 
FLT3. Mutations in the receptor tyrosine kinase FLT3 
occurs in more than 30% of AML patients [1]. The internal 
tandem duplication (ITD) is a repetition of sequence that 
encodes the juxtamembrane domain and is the most com-
mon oncogenic mutations in FLT3 that correlates with a 
poor prognosis [2]. Other oncogenic mutations include 
point mutations or ITD mutations in the kinase domain.
FLT3 belongs to the type III receptor tyrosine kinase 
(RTK) family that includes five members PDGFRA, PDG-
FRB, KIT, CSF1R and FLT3. The characteristic feature 
of this family is an extracellular domain consisting of five 
immunoglobulin-like domains and an intracellular kinase 
domain interrupted by a kinase insert. The extracellular 
domain mediates association of the dimeric ligand and 
thereby induces dimerization of the receptor. Dimerization 
of receptor initiates a tyrosine phosphorylation program 
resulting in phosphorylation of several tyrosine residues 
in the receptor which are essential both for receptor activa-
tion and signal propagation [3]. Activation of FLT3 subse-
quently activates downstream signaling cascades including 
PI3K-AKT and RAS-ERK signaling through various SH2 
domain-containing proteins such as GAB2, SHC and SHP2 
[3]. Although wild-type FLT3 requires its ligand FLT3 
ligand (FL) for activation, oncogenic mutants are constitu-
tively active. Oncogenic FLT3 binds essentially to the same 
docking molecules as wild-type FLT3, and therefore con-
trols similar signaling pathways [4].
The FLT3-ITD mutations significantly increase the 
risk of relapse, and therefore limit disease-free and over-
all survival [2, 5]. Inhibition of FLT3 displayed promising 
results in clinical trials [6]. However, in most of the cases 
responses were not sufficient for treatment of AML with a 
single drug [6]. Inhibitors mostly reduce peripheral blood 
blasts transiently, and bone marrow responses are rare 
[7, 8]. Limited response to the inhibitors is mainly due to 
primary and secondary mutations in FLT3 that make the 
receptor resistant to the inhibitor [9]. The second-genera-
tion FLT3 inhibitor, AC220 (quizartinib), induced a com-
posite complete remission rates of 44–54% which is much 
better than that observed with other FLT3 inhibitors. How-
ever, later studies indicate that treatment with this drug also 
suffers from problems of acquired secondary resistance 
[10]. A recent study suggests that the multi-kinase inhibi-
tor midostaurin prolongs survival when used in combina-
tion with chemotherapy [11]. Thus, we still need a better 
understanding of the best way of targeting FLT3 for AML 
treatment.
Phosphorylation of the tyrosine residue in the activa-
tion loop is known to be the hallmark of activation of 
many tyrosine kinases. For example, phosphorylation of 
activation loop tyrosine residues of fibroblast growth fac-
tor receptor leads to a 500 to 1000-fold increase in sub-
strate phosphorylation [12], and is also crucial for activa-
tion of the insulin receptor [13] and hepatocyte growth 
factor receptor (MET) [14]. However, in both KIT and the 
PDGFR activation of the receptors intrinsic kinase activity 
was independent of phosphorylation of the activation loop 
tyrosine residue [15–17]. In this report, we show that the 
activation loop tyrosine is critical for FLT3-induced down-




Human recombinant FLT3 ligand was from ORF genet-
ics (Kópavogur, Iceland). The transfection reagent Lipo-
fectamine 2000 was from Thermo Scientific and cyclohex-
imide was from Sigma-Aldrich. pcDNA3-FLT3-WT, 
pMSCVpuro-FLT3-WT and pMSCVpuro-FLT3-ITD were 
described previously [18]. pMSCVpuro-FLT3-WT/Y842F 
and pMSCVpuro-FLT3-ITD/Y842F plasmids were gen-
erated by site-directed mutagenesis using QuikChange 
mutagenesis XL kit (Agilent Technologies). The anti-FLT3 
antibody was a rabbit polyclonal antibody produced in-
house. Mouse monoclonal anti-beta-actin, horseradish per-
oxidase-conjugated anti-FLAG antibody and mouse mono-
clonal anti-FLAG antibodies were from Sigma-Aldrich. 
Mouse anti-phosphotyrosine (4G10) antibody and mouse 
mono-ubiquitin antibody were from Millipore and Covance 
Research Products, respectively. Rabbit anti-ERK2, rabbit 
anti-phospho ERK1/2 (pThr202/pThr204), goat anti-AKT 
antibodies were from Santa Cruz Biotechnology. Rabbit 
anti-tubulin, rabbit anti-phospho-AKT (pSer473) rabbit 
anti-phospho GAB2 and rabbit anti-phospho-SHP2 were 
from Cell Signaling Technology.
Cell culture, transient and stable transfection
COS-1 and 32D cells were obtained from Deutsche 
Sammlung von Mikroorganismen und Zellen (DSMZ). 
COS-1 cells were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum 
(FBS), 100 µg/ml streptomycin and 100 units/ml penicillin. 
32D cells were cultured in RPMI 1640 medium containing 
10% heat-inactivated fetal bovine serum (FBS), 100 µg/ml 
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streptomycin and 100  units/ml penicillin. Transient trans-
fection of COS-1 cells and stable transfection of 32D cells 
were described previously [19]. Transfected 32D cells were 
maintained in the IL3-containing medium as described ear-
lier [20].
Immunoprecipitation and western blotting
COS-1 cells were washed with cold PBS after 100 ng/ml 
ligand stimulation and lysed with Triton-X 100-based lysis 
buffer. 32D cells were starved of cytokines and serum for 
4 h before stimulation. After stimulation cells were washed 
with cold PBS before lysis. Each ml of cell lysates was 
immunoprecipitated with 1 µg antibody and then processed 
for SDS-PAGE and western blotting analysis using the 
standard protocol [21].
Cell viability, apoptosis and colony formation assays
32D cells were washed three times to remove cytokines and 
re-suspended in RPMI 1640 containing 10% FBS. Presto-
Blue cell viability assay and apoptosis assay were described 
previously [22]. Colony formation assay was performed as 
described elsewhere [23].
Animal experiment
Five male BALB/c nude mice in each group were used for 
animal experiments following Hong Kong animal ethi-
cal regulations. Mice were injected subcutaneously with 
1,000,000 cells in 100 µl (1:1) PBS and Matrigel mixture. 
Mice were monitored for weight change and tumor size.
Gene expression analysis using microarray
32D cells expressing FLT3-ITD or FLT3-ITD/Y842F were 
washed three times to remove cytokines and serum. Cells 
were starved in medium containing 0.5% serum overnight 
before extraction of total RNA using the RNeasy mini kit 
(Qiagen). Bio-analyzer was used to check the quality of 
RNA. Gene expression was analyzed using Affymetrix 
GeneChip Mouse Gene 2.0 ST arrays. Raw data were nor-
malized using RMA normalization.
Statistical analysis
All in  vitro experiments were performed at least three 
times. Student’s t test and one-way ANOVA with Bonfer-
roni’s post-tests were used for statistical analysis using 
GraphPad prism 5.0. Data were expressed as the mean ± SE 
and two-way t test was used.
Results
Expression of the FLT3/Y842F mutant results 
in reduced cell proliferation and enhanced apoptosis 
in myeloid cells
We have recently demonstrated that the activation loop 
tyrosine is of importance for KIT-mediated mitogenic 
signaling and KIT/D816V-mediated oncogenic transfor-
mation [15, 16]. Since FLT3 belongs to the same fam-
ily of receptor tyrosine kinases as KIT, we hypothesized 
that the analogous FLT3 mutant would display a similar 
phenotype. We transduced a myeloid cell line, 32D lack-
ing endogenous FLT3 expression, with oncogenic FLT3-
ITD as well as with an activation loop tyrosine-to-phe-
nylalanine mutant in ITD background, FLT3-ITD/Y842F. 
Since 32D cells are cytokine-dependent, withdrawal of 
cytokines leads to complete growth inhibition as well 
as to cell death. Both transfected cell lines displayed 
same cell surface expression of FLT3 (Fig. 1a, S1A and 
S1B) as well as total expression of FLT3 (Fig.  1b). We 
observed that while FLT3-ITD could fully support the 
viability of cytokine-starved 32D cells, FLT3-ITD-Y842F 
expressing cells displayed reduced viability. This sug-
gests that, similar to KIT, phosphorylation of the FLT3 
activation loop tyrosine is required for maintenance of 
cell viability (Fig.  1c). We also observed a significant 
increase in apoptosis in cytokine-starved cells express-
ing the FLT3-ITD/Y842F mutant compared to FLT3-ITD 
expressing cells (Fig. 1d).
Cells expressing the Y842F mutant have an impaired 
capacity to form colonies in vitro and tumors in vivo
As we observed that the FLT3-ITD/Y842F mutant cells 
had reduced cell viability and higher levels of apopto-
sis, we checked for their ability of in  vitro colony for-
mation in a semi-solid medium. We observed that cells 
expressing FLT3-ITD/Y842F induced a significantly 
lower number of colonies (Fig. 2a) as well as a reduced 
colony size (Fig. 2b) suggesting that the Y842F mutation 
reduces the transformation potential of FLT3-ITD. To 
verify our in vitro data in an animal model, we generated 
a mouse xenograft model by injecting 32D cells subcuta-
neously. The FLT3-ITD/Y842F mutant displayed signifi-
cantly delayed tumor formation in xenotransplanted mice 
(Fig. 2c). Average tumor weight was reduced by 70% in 
mice injected with cells expressing FLT3-ITD-Y842F 
(Fig.  2d, e) compared to mice injected with FLT3-ITD 
expressing cells, suggesting that the phosphorylation 
of the activation loop tyrosine is an important event in 
FLT3-ITD-mediated transformation.
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Y842F mutation leads to downregulation of oncogenic 
signaling
As we observed that the Y842F mutation diminishes 
FLT3-ITD-mediated cell viability, colony formation and 
tumor formation, we hypothesized that this mutation might 
influence FLT3-ITD-induced gene expression. Thus, we 
checked global gene expression using Affymetrix Mouse 
Gene 2.0 ST arrays (EMBL-EBI arrayexpress accession: 
E-MTAB-5258). Cells expressing FLT3-ITD or FLT3-
ITD/Y842F display difference in gene expression patterns 
(Fig. 3a) indicating that Y842F mutation influences FLT3-
ITD-mediated gene expression. Expression of anti-apop-
totic genes and oncogenes was suppressed in cells express-
ing the Y842F mutant (Fig.  3b). We then used the gene 
set which were downregulated in cells expressing Y842F 
mutant and analyzed for gene ontology using DAVID 
Functional Annotation Bioinformatics Microarray Analysis 
(https://david.ncifcrf.gov). Result showed an enrichment 
of GO:0070374 (positive regulation of ERK1 and ERK2 
cascade, p = 3.405E−08). Moreover, gene set enrichment 
analysis (GSEA) suggests that the deregulated genes are 
involved in several oncogenic pathways such as KRAS, 
SRC and loss of p53 (Fig. 3c). Since oncogenic signature 
genes were downregulated in Y842F expressing cells, it 
suggests that FLT3-ITD/Y842F has an impaired oncogenic 
capacity.
Y842F mutation selectively inhibited FL-induced 
ERK1/2 activation
To understand how mutation at Y842 affects FLT3-induced 
normal biological outcomes, we generated 32D cell lines 
expressing FLT3-WT and FLT3-WT/Y842F. Both cell lines 
expressed equal levels of FLT3 on the cell surface (Fig. 4a, 
S1C and S1D) as well as total FLT3 (Fig.  4b). Although 
expression of FLT3-ITD can partially support the growth 
of 32D cells upon cytokine withdrawal, cells express-
ing wild-type FLT3 cannot support the cell survival even 
when supplemented with FL. We analyzed FLT3 down-
stream signaling following stimulation with FLT3 ligand 
using phospho-specific antibodies. We observed that ligand 
stimulation of cells expressing the Y842F mutant activated 
phosphorylation of AKT to an equal extent as wild-type 
FLT3 (Fig.  4c). In contrast, mutation of Y842F led to a 
dramatic reduction in ERK1/2 phosphorylation (Fig.  4d). 
Similarly, FLT3-ITD-mediated constitutive activation of 
ERK1/2, but not AKT, was partially blocked by the Y842F 
Fig. 1  Y842F mutation reduces cell viability and increases apopto-
sis. a Cell surface expressions of FLT3-ITD and FLT3-ITD/Y842F in 
stably transfected 32D cells were analyzed by flow cytometry using 
PE-conjugated anti-FLT3 antibody. b 32D cells expressing FLT3-ITD 
and FLT3-ITD/Y842F were lysed and lysates were analyzed using 
SDS-PAGE and western blotting. c Cell viability was measured upon 
cytokine depletion using PrestoBlue cell viability assay after 48 and 
72 h. d Apoptosis was measured after 48 and 72 of cytokine depletion 
using Annexin V and 7AAD kit. ***p < 0.001; **p < 0.01; ns not sig-
nificant; error bar represents SEM
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mutation. However, we have not seen any reduction of 
STAT5 phosphorylation in cells expressing Y842F mutant 
(Fig. S2).
FLT3-Y842F mutant displays impaired SHP2 activation
FLT3 induces ERK1/2 activation through multiple sign-
aling cascades. The two key signaling molecules, GAB2 
and SHP2, are involved in this pathway [3]. Therefore, 
we examined the levels GAB2 and SHP2 phosphoryla-
tion following FL stimulation. We observed that while the 
presence or absence of the Y842F mutation did not affect 
GAB2 phosphorylation, the phosphorylation of SHP2 was 
strongly decreased in cells expressing the Y842F mutant 
(Fig.  5a). This observation suggests that somehow phos-
phorylation of Y842 in the activation loop is required for 
FLT3-mediated SHP2 phosphorylation which in turn is 
involved in activation of ERK1/2 signaling. We have pre-
viously demonstrated that SHP2 associated with phos-
photyrosine Y599 in FLT3 [24]. Since we did not see a 
difference in phosphorylation of GAB2 (which in other sys-
tems has been demonstrated to associate with SHP2) in the 
Y842F mutant, it is likely that Y842 is an important SHP2 
association site in FLT3. We observed that while wild-
type FLT3 was able to associate with SHP2, the ligand-
activated Y842F mutant displayed reduced SHP2 interac-
tion (Fig.  5b) suggesting that Y842 is one of the binding 
sites for SHP2 in FLT3, either directly or indirectly. To 
determine whether SHP2 directly associates with pY842, 
we used a synthetic phospho-peptide corresponding to 
the FLT3-Y842 site. We did not observe any association 
between SHP2 and the FLT3-pY842 peptide suggesting 
that pY842 is not a direct binding site for SHP2 (Fig. 5c). 
However, we cannot exclude the possibility that an adapter 
protein bridges the binding of SHP2 to FLT3. Another pos-
sible explanation of the reduced binding capacity of the 
FLT3-Y842F mutant is that it could be due to a reduction 
in FLT3-Y599 phosphorylation. Therefore, we compared 
FLT3-Y599 phosphorylation between wild-type and Y842F 
mutant. We did not observe any reduction of FLT3-Y599 
Fig. 2  Y842F mutant has impaired colony formation and tumor 
formation capacity. a, b Cells were washed to remove cytokine and 
serum and seeded in methylcellulose medium. Colonies were counted 
7  days after seeding. c–e Immunocompromised mice were injected 
subcutaneously with 32D cells expressing FLT3-ITD or FLT3-ITD-
Y842F. Tumor volume was measured twice a week and tumor weight 
was measured after killing mice. ***p < 0.001; ns not significant; 
error bar represents SEM
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site phosphorylation in Y842F expressing cells suggesting 
that the activation loop tyrosine has no role in regulating 
FLT3-Y599 phosphorylation (Fig. 5d).
Mutation of the Y842 residue has no effect 
on ubiquitination or phosphorylation of FLT3 but leads 
to reduced stability of the protein
Ligand stimulation results in dimerization of FLT3 fol-
lowed by autophosphorylation at several tyrosine residues, 
which in turn creates docking sites for, among other things, 
the ubiquitin E3 ligase CBL. In a previous report, we 
observed that ligand stimulation of wild-type KIT versus 
ligand stimulation of the activation loop tyrosine mutant of 
KIT (Y823F) leads to differential tyrosine phosphorylation 
as well as ubiquitination patterns [16]. In this study, we did 
not see any significant difference in ligand-induced ubiq-
uitination or tyrosine phosphorylation between wild-type 
FLT3 and FLT3/Y842F (Fig. 6a). However, FLT3 degrada-
tion was increased by approximately 30% following ligand 
stimulation (Fig.  6b) in the Y824F mutant compared to 
wild-type FLT3.
Discussion
Oncogenic mutations in FLT3 lead to aberrant activation 
of survival and proliferation signaling. The most frequent 
Fig. 3  Y842F mutation changes FLT3-ITD-induced gene expres-
sion. a Heat map shows the difference in gene expression in between 
FLT3-ITD and FLT3-ITD-Y842F. b Upregulated and downregulated 
genes in Y842F mutant. c Gene set enrichment analysis between 
FLT3-ITD and FLT3-ITD-Y842F transfected cells shows enrichment 
of different oncogenic signatures
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gain-of-function mutation, FLT3-ITD, is a potent and 
constitutive activator of downstream signaling. Other 
gain-of-function mutations include point mutations in 
the tyrosine kinase domain such as D835Y. Mutation in 
the tyrosine kinase domain also occurs in combination 
with a FLT3-ITD mutation leading to resistance to sev-
eral FLT3 kinase inhibitors. Mutations of the activation 
loop tyrosine of FLT3 (Y842) is a less frequent event in 
leukemia. One report suggested that Y842C mutation 
results in constitutive activation of the receptor [25]. 
Y842C or Y842H mutations in combination with FLT3-
ITD led to resistance to FLT3 kinase inhibitors [26, 27]. 
In the crystal structure of autoinhibited FLT3, Y842 
makes extensive interactions with neighboring amino 
acid residues and thereby stabilizes the DFG-out inac-
tive form of FLT3 [10, 17]. Mutation of Y842 to either 
H or C would likely result in loss of these interaction and 
lead to destabilization of the inactive form of FLT3. In 
contrast, mutation to F does most likely not interfere with 
the hydrophobic interactions and thus does not activate 
FLT3. Interestingly, in the closely related RTK KIT acti-
vating mutations have also been described at the homolo-
gous tyrosine residue, Y823. Different substitution muta-
tions of this residue have been found but while Y823D 
is a constitutively active mutant [28], Y823A is kinase 
inactive [29] and Y823F does not affect kinase activity 
[16, 29].
To understand the functional role of Y842 we generated 
an Y842F mutant which is identical to wild-type FLT3 with 
the exception of the hydroxyl group missing in this posi-
tion, thus preventing it from being tyrosine phosphorylated. 
We observed that Y842 is of great importance for FLT3-
induced downstream signaling despite the fact that it does 
not affect the kinase activity of FLT3.
Fig. 4  Y842F mutation selec-
tively reduces ERK phosphoryl-
ation. a Cell surface expressions 
of FLT3-WT and FLT3-WT/
Y842F in stably transfected 
32D cells were analyzed by flow 
cytometry using PE-conjugated 
anti-FLT3 antibody. b 32D 
cells expressing FLT3-WT and 
FLT3-WT/Y842F were lysed 
and lysates were analyzed using 
SDS-PAGE and western blot-
ting. c, d Cells were serum and 
cytokine starved for 4 h before 
stimulating with 100 ng/ml FL 
for different time points. Cells 
were then lysed and lysates 
were used for SDS-PAGE and 
western blotting analysis using 
anti-phospho-AKT (c) and anti-
phospho-ERK1/2 (d) antibodies
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Fig. 5  Y842F mutation reduces 
SHP2 phosphorylation. a Cells 
were serum- and cytokine-
starved for 4 h before stimu-
lating with 100 ng/ml FL for 
different time points. Cells were 
then lysed and lysates were used 
for SDS-PAGE and western 
blotting analysis using anti-
phospho-GAB2 and anti-phos-
pho-SHP2 antibodies. b COS-1 
cells were transfected with 
FLAG-tag SHP2 and FLT3-WT 
or FLT3-WT/Y842F. One day 
after transfection cells were 
stimulated with 100 ng/ml FL 
for 5 min before lysis. Lysates 
were immunoprecipitated using 
1 µg anti-FLAG antibody. 
***p < 0.001; error bar repre-
sents SEM. c Phospho-peptides 
corresponding to the different 
FLT3 phosphorylation sites 
were coupled to Ultralink beads. 
Slurry of immobilized peptides 
was incubated with cell lysates 
from SHP2 expressing cells. d 
Cells were serum-starved for 
4 h before stimulation followed 
by lysis. Lysates were used for 
immunoprecipitation followed 
by western blotting analysis
Fig. 6  Y842F mutation 
increases FLT3 degradation. a 
Cells were serum- and cytokine-
starved for 4 h before stimu-
lating with 100 ng/ml FL for 
different time points. Cells were 
then lysed and lysates were 
immunoprecipitated using 1 µg 
anti-FLT3 antibody. b Cells 
were treated with cyclohex-
imide for 30 min followed by 
30 min of ligand stimulation. 
Cells were then lysed and 
lysates were used to measure 
degradation. **p < 0.01; error 
bar represents SEM
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Although phosphorylation of the activation loop tyros-
ine residues is critical for the kinase activity of several 
receptor tyrosine kinases such as the fibroblast growth 
factor receptor, the insulin receptor and MET [12–14], 
data suggest that it is dispensable for activation of type 
III RTKs [15–17]. However, Y842 in FLT3 and the cor-
responding residue in KIT (Y823) play important roles 
in receptor signaling as well as in transformation medi-
ated by oncogenic mutants of either RTK. We observed 
that the Y842F mutation significantly reduced FLT3-
ITD-induced cell viability and induced apoptosis in 
transfected 32D cells suggesting that Y842 plays a role 
in survival signaling mediated by oncogenic FLT3. Fur-
thermore, the Y842F mutant cells exhibited impaired 
transforming capacity displayed as a reduced capacity 
to form colonies, which also were smaller, as well as 
reduced capacity to form tumors in xenografted mice. 
Thus, Y842F mutation displays in the FLT3-ITD back-
ground a similar phenotype to the Y823F mutation in the 
KIT/D816V background [15], in that it severely limits the 
oncogenic capacity of the transforming mutant.
Although the Y823F mutation suppresses several 
signaling pathways downstream of KIT, including AKT, 
ERK1/2 and p38 [16], the Y842F mutant of FLT3 selec-
tively reduced only FLT3-mediated ERK1/2 signal-
ing, while AKT signaling was intact. This further sup-
ports the notion that the receptor activation per se is not 
affected but selective downstream signaling events. The 
suppression of ERK1/2 signaling that we observed in 
mutant cells is likely to be due to the impaired activa-
tion of SHP2 signaling. SHP2 is a potent binding partner 
of FLT3, phosphorylated by FLT3 [30] and required for 
FLT3-mediated downstream signaling [24]. Activation of 
SHP2 occurs through binding of its two SH2 domains to 
phosphotyrosine residues, that leads to a conformational 
change and activation of its intrinsic protein tyrosine 
phosphatase activity [29]. Despite being a phosphatase, 
SHP2 is linked to positive signaling and activation of the 
RAS/ERK pathway through several mechanisms (for a 
review, see [10]). The observation that mutation of Y842 
significantly reduced SHP2 interaction with FLT3 indi-
cates that the impaired activation of ERK1/2 signaling 
in Y842F mutant cells is due to the reduced binding of 
SHP2 to FLT3 and reduced activation. The Y842F muta-
tion did not completely eliminate the binding of SHP2, 
which can be explained by Y599 being an additional 
SHP2 binding site [24]. Taken together, our data sug-
gests a unique function of the activation loop tyrosine 
residue in FLT3. Given the importance of both the activa-
tion loop and SHP2 in FLT3-ITD-mediated transforma-
tion, the development of drugs that interfere with bind-
ing of SHP2 to Y842 or with the activity of SHP2 could 
be useful drugs for the treatment of patients with acute 
leukemia.
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